Venus Remedies Limited — Board Meeting, 29-01-2026: Outcome of Board Meeting
29-01-2026 | 06:01 pm
29-01-2026 | 06:01 pm
Venus Remedies' board approved Q3 & nine-month results. Consolidated Revenue from Operations hit ₹180.26 Cr, Net Profit ₹25.58 Cr. Subsidiary Venus Pharma GmbH faces negative net worth (₹0.94 Cr), but management expects recovery and stability by FY26 end.
No comments yet. Be the first to comment!
